Testing eltrombopag in patients with acute myelogenous leukemia (AML) who receive chemotherapy with daunorubicin plus cytarabine

Registry ID

EUCTR2013-000642-20

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

GlaxoSmithKline Research and Development Ltd

Start date

2013-06-28

Completion date

2017-01-25

Last update

2026-08-16

Conditions

• Acute myelogenous leukemia

Summary

To assess the safety and tolerability of eltrombopag versus placebo in subjects receiving standard induction therapy for acute myeloid leukemia (AML)

Locations

• , , Hungary
• , , Greece
• , , Belgium
• , , Poland

Related clinical trials

• Register AML-BFM 2017 for the registration of acute myelogenous leukemia in children and adolescents

View on source registry